Tilray Brands, Inc. TLRY
Medicinal Chemicals and Botanical Products · IPO 2018 · data as of November 13, 2026
Tilray Brands, Inc. (TLRY) is a healthcare company listed in the US with a market value of about $359M. In the twelve months to August 31, 2026 it had revenue of $963M and net income of -$164M, a net margin of -17.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of -38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
About Tilray Brands
Tilray Brands is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2018. Revenue went from $43M in 2018 to $915M in 2026, growth of about 46.5% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 81% over three years (dilution for shareholders). It spends 0% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $963M | $915M | $821M | $789M | $627M | $628M | $513M | $210M | $167M | $43M |
| Net income | -$164M | -$121M | -$2.2B | -$245M | -$1.5B | -$477M | -$367M | -$271M | -$321M | -$68M |
| Free cash flow | -$119M | — | -$128M | -$60M | -$13M | -$211M | -$84M | -$174M | -$332M | -$96M |
| EPS (diluted) | $-1.41 | $-1.09 | $-24.56 | $-3.30 | $-23.50 | $-9.90 | $-13.60 | $-21.50 | $-32.00 | $-8.20 |
| Net margin | -17.1% | -13.3% | -266.2% | -31.1% | -231.6% | -75.9% | -71.6% | -128.8% | -192.3% | -157.0% |
| ROIC | — | -2.9% | -132.6% | -4.3% | -36.6% | -13.1% | -2.8% | -45.0% | -97.8% | -27.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $5.72, 135% above the current price; targets range from $4.00 to $13.00; the consensus rating is “Buy”; expected EPS is $-0.13 for the fiscal year ending May 31, 2027.
Frequently asked questions
Is Tilray Brands stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Tilray Brands pay a dividend?
Not currently.
Is Tilray Brands a good stock to buy?
We do not give buy or sell advice. Tilray Brands scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.